ALGS

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-97.7K ExitQ3 2024 $98k -- $5.74
Jim SimonsRenaissance Technologies $-269.1K ExitQ3 2024 $269k -- $5.74

News

gurufocus.comMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressivagurufocus.comJun 14

gurufocus.comMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026gurufocus.comJun 4

gurufocus.comMirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026gurufocus.comMay 30

globenewswire.comAligos Therapeutics Presents Positive Data at the EASL Congress 2026globenewswire.comMay 27

Trade ALGS

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.

CEO: Lawrence Blatt
IPO Date: Oct 16, 2020

Market Data

Open: $5.25
High: $5.39
Low: $5.16
Volume: 37.2K
Avg Volume: 211.5K
52W High: $13.69
52W Low: $4.80

Valuation

Market Cap: $32.7M
Enterprise Value: $6.9M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$82.9M
Revenue: $2.2M
Net Income: -$24.2M
Cash: $18.3M
Debt: $5.3M

Events

EarningsAug 5

EPS est. -1.24885